monocarboxylic acid catechols carbidopa (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1) (S)-(-)-carbidopa hydrate (S)-carbidopa hydrate (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate 244.106 244.24440 C10H16N2O5 CAS:38821-49-7 CHEBI:212626 CHEBI:3395 DrugBank:DB00190 InChI=1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1 KEGG:D00558 L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate O.C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O PMID:10841799 Patent:DE2062285 Patent:DE2062332 Patent:GB940596 Patent:US3462536 QTAOMKOIBXZKND-PPHPATTJSA-N The hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. carbidopa carbidopa hydrate carbidopa monohydrate carbidopum monohydricum chebi_ontology hydrate nitrogen molecular entity